샘플 요청 목록

 카트 문의
시장보고서
상품코드
1880826

세계의 백혈병 치료제 시장

Leukemia Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 백혈병 치료제 시장은 2030년까지 259억 달러에 달할 전망

백혈병 치료제 세계 시장은 2024년에 186억 달러로 추정되며, 2030년까지 259억 달러에 달할 것으로 예측됩니다. 2024년부터 2030년까지 분석 기간 동안 CAGR 5.6%로 성장할 전망입니다. 이 보고서에서 분석 대상이 된 부문 중 하나인 만성 골수성 백혈병 치료제는 5.3%의 CAGR을 기록하며 분석 기간 종료까지 91억 달러에 달할 것으로 예측됩니다. 만성 림프구성 백혈병 치료제 부문의 성장률은 분석 기간 동안 6.5%의 CAGR로 추정됩니다.

미국 시장은 49억 달러로 추정되는 한편 중국은 8.4%의 CAGR로 성장할 것으로 예측됩니다

미국의 백혈병 치료제 시장은 2024년에 49억 달러로 추정됩니다. 세계 2위의 경제 규모를 자랑하는 중국은 2024년부터 2030년까지의 분석 기간 동안 CAGR 8.4%를 기록하며 2030년까지 58억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장 분석으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 2.9%와 5.0%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 3.3%의 CAGR로 성장할 것으로 예측됩니다.

백혈병 치료제 세계 시장 - 주요 시장 동향 및 촉진요인 개요

백혈병 치료제 수요가 급증하는 이유

백혈병 치료제 시장은 전 세계적으로 백혈병 발생률이 지속적으로 증가함에 따라 빠르게 성장하고 있습니다. 혈액과 골수에 영향을 미치는 암의 일종인 백혈병은 고령화, 환경적 요인 등의 영향으로 환자 수가 증가하고 있습니다. 효과적인 치료법에 대한 수요가 증가하면서 표적 치료제, 면역치료제, 병용요법 등 새로운 치료법 개발이 활발히 진행되고 있습니다. 이러한 첨단 치료법은 환자의 생존율을 높이고 삶의 질을 향상시켜 의료진들 사이에서 점점 더 많은 인기를 얻고 있습니다. 효과적인 백혈병 치료의 필요성이 증가함에 따라 백혈병 치료제 시장은 크게 확대될 것으로 예상됩니다.

기술 혁신은 백혈병 치료를 어떻게 변화시키고 있는가?

기술 혁신은 백혈병 치료의 지형을 바꾸고 있으며, 보다 표적화되고 효과적인 치료법 개발을 주도하고 있습니다. 유전체학 및 분자생물학의 발전으로 다양한 종류의 백혈병과 관련된 특정 유전자 변이를 식별할 수 있게 되어 맞춤형 의료의 길을 열었습니다. 티로신 키나아제 억제제(TKI)와 같은 표적 치료제는 건강한 세포에 미치는 영향을 최소화하면서 암세포를 특이적으로 공격하도록 설계되어 부작용을 줄이고 환자의 치료 성적을 향상시키고 있습니다. 또한, 유전자 조작된 T세포를 이용해 백혈병 세포를 표적으로 삼는 면역치료의 일종인 CAR-T 세포 치료의 등장은 특정 백혈병 환자의 치료 옵션에 혁명을 일으키고 있습니다. 이러한 기술적 발전은 백혈병 치료 효과를 높일 뿐만 아니라 시장 성장을 견인하고 있습니다.

백혈병 치료의 새로운 트렌드는?

백혈병 치료제 시장을 형성하는 새로운 트렌드로는 병용요법의 증가, 바이오시밀러 개발, 면역요법에 대한 관심 증가 등을 꼽을 수 있습니다. 여러 약제와 치료법을 결합한 병용요법은 약제 내성 극복과 치료 성과 향상에 유망한 결과를 보여주고 있습니다. 바이오의약품을 대체할 수 있는 저비용 대안인 바이오시밀러의 개발은 특히 신흥시장에서 치료 접근성을 확대할 것으로 기대되고 있습니다. 면역치료, 특히 CAR-T 세포 치료는 특정 백혈병 유형에 대한 매우 효과적인 치료 옵션으로 주목받고 있으며, 기존 치료법에 반응하지 않는 환자들에게 새로운 희망을 가져다주고 있습니다. 이러한 추세는 새로운 치료 옵션이 속속 등장하면서 백혈병 치료제 시장의 역동적인 성장에 기여하고 있습니다.

백혈병 치료제 시장의 성장을 이끄는 요인은 무엇일까?

백혈병 치료제 시장의 성장은 백혈병 발병률 증가, 치료법 발전, 맞춤형 의료에 대한 수요 증가 등 여러 요인에 의해 주도되고 있습니다. 표적 치료제와 면역치료제의 개발은 환자들에게 새로운 희망을 가져다주며 시장 확대를 견인하고 있습니다. 또한, 백혈병에 초점을 맞춘 임상시험 및 연구 활동의 증가는 새로운 치료법 개발을 가속화하고 있습니다. 종양학 연구에 대한 자금 조달과 투자 확대도 시장 성장을 촉진하고 있습니다. 백혈병에 대한 이해가 깊어지고 새로운 치료법이 개발됨에 따라 보다 효과적이고 접근하기 쉬운 치료법에 대한 수요에 힘입어 백혈병 치료제 시장은 지속적인 성장을 이룰 것으로 예상됩니다.

부문:

백혈병 종류(만성 골수성 백혈병, 만성 림프구성 백혈병, 급성 림프구성 백혈병, 급성 골수성 백혈병), 분자 유형(저분자 화합물, 생물학적 제제), 치료 유형(화학요법, 표적 치료제, 면역요법, 기타 치료 유형)

조사 대상 기업 예시

  • AbbVie, Inc.
  • Altor Bioscience(NANT Company)
  • Amgen, Inc.
  • Arno Therapeutics, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer Healthcare AG
  • Bellicum Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Emergent BioSolutions, Inc.
  • Erytech Pharma
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Inc.
  • Immune Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Jazz Pharmaceuticals PLC
  • Juno Therapeutics Inc.
  • Meda AB
  • MedImmune LLC
  • Merck & Co., Inc.
  • Midas Pharma GmbH
  • Nippon Shokubai Co., Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Orphan Europe SARL
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Portola Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • XEME Biopharma Inc.
  • Xencor, Inc.
  • ZIOPHARM Oncology, Inc.

AI 통합

검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보를 혁신하고 있습니다.

Market Glass, Inc.는 LLM이나 산업 특화형 SLM을 쿼리하는 일반적인 방식이 아닌, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색 엔진 조사, 그리고 방대한 양의 기업, 제품/서비스, 시장 데이터가 포함됩니다.

관세 영향 계수

Market Glass, Inc.가 본사 소재지, 생산기지, 수출입(완제품 및 OEM)에 따라 기업의 경쟁력 변화를 예측하는 과정에서 지리적 시장에 대한 관세의 영향을 반영하였습니다. 이러한 복잡하고 다면적인 시장 현실은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 경쟁사에게 다양한 영향을 미치며, 미시적 및 거시적 시장 역학에도 영향을 미칩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.12.11

Global Leukemia Therapeutics Market to Reach US$25.9 Billion by 2030

The global market for Leukemia Therapeutics estimated at US$18.6 Billion in the year 2024, is expected to reach US$25.9 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia Therapeutics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of the analysis period. Growth in the Chronic Lymphocytic Leukemia Therapeutics segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 8.4% CAGR

The Leukemia Therapeutics market in the U.S. is estimated at US$4.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Leukemia Therapeutics Market - Key Trends & Drivers Summarized

Why Is the Demand for Leukemia Therapeutics Growing Rapidly?

The leukemia therapeutics market is experiencing rapid growth as the incidence of leukemia continues to rise globally. Leukemia, a type of cancer affecting the blood and bone marrow, has seen an increase in cases due to factors such as aging populations and environmental influences. The growing demand for effective treatments is driving the development of new therapies, including targeted drugs, immunotherapies, and combination treatments. These advanced therapies are offering improved survival rates and better quality of life for patients, making them increasingly popular among healthcare providers. As the need for effective leukemia treatments grows, the market for leukemia therapeutics is expected to expand significantly.

How Are Technological Innovations Transforming Leukemia Treatment?

Technological innovations are transforming the landscape of leukemia treatment, leading to the development of more targeted and effective therapies. Advances in genomics and molecular biology have enabled the identification of specific genetic mutations associated with different types of leukemia, paving the way for personalized medicine. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), are designed to specifically attack cancer cells with minimal impact on healthy cells, reducing side effects and improving patient outcomes. Additionally, the rise of CAR-T cell therapy, a type of immunotherapy that uses genetically modified T cells to target leukemia cells, is revolutionizing treatment options for patients with certain types of leukemia. These technological advancements are not only enhancing the effectiveness of leukemia therapies but are also driving growth in the market.

What Are the Emerging Trends in Leukemia Therapeutics?

Several emerging trends are shaping the leukemia therapeutics market, including the increasing use of combination therapies, the development of biosimilars, and the growing focus on immunotherapy. Combination therapies, which involve using multiple drugs or treatment modalities, are showing promise in overcoming drug resistance and improving treatment outcomes. The development of biosimilars, which are lower-cost alternatives to biologic drugs, is expected to increase access to treatment, particularly in emerging markets. Immunotherapy, particularly CAR-T cell therapy, is gaining traction as a highly effective treatment option for certain types of leukemia, offering new hope for patients who have not responded to traditional therapies. These trends are contributing to the dynamic growth of the leukemia therapeutics market, as new treatment options continue to emerge.

What Factors Are Driving the Growth of the Leukemia Therapeutics Market?

The growth in the leukemia therapeutics market is driven by several factors, including the increasing prevalence of leukemia, advancements in treatment options, and the rising demand for personalized medicine. The development of targeted therapies and immunotherapies is providing new hope for patients and driving market expansion. Additionally, the growing number of clinical trials and research activities focused on leukemia is accelerating the development of new treatments. The availability of funding and investment in oncology research is also fueling market growth. As the understanding of leukemia continues to improve and new therapies are developed, the leukemia therapeutics market is expected to experience sustained growth, driven by the need for more effective and accessible treatments.

SCOPE OF STUDY:

The report analyzes the Leukemia Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type of Leukemia (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia); Molecule Type (Small Molecules, Biologics); Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Other Treatment Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie, Inc.
  • Altor Bioscience (a NANT Company)
  • Amgen, Inc.
  • Arno Therapeutics, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer Healthcare AG
  • Bellicum Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Emergent BioSolutions, Inc.
  • Erytech Pharma
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Inc.
  • Immune Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Jazz Pharmaceuticals PLC
  • Juno Therapeutics Inc.
  • Meda AB
  • MedImmune LLC
  • Merck & Co., Inc.
  • Midas Pharma GmbH
  • Nippon Shokubai Co., Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Orphan Europe SARL
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Portola Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • XEME Biopharma Inc.
  • Xencor, Inc.
  • ZIOPHARM Oncology, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Leukemia Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Leukemia Spurs Growth in the Leukemia Therapeutics Market
    • Advancements in Targeted Therapy Propel Adoption of Novel Leukemia Treatments
    • Growing Application of Combination Therapies Strengthens Market Demand in Leukemia Treatment
    • Shift Towards Personalized Medicine Expands Addressable Market for Leukemia Therapeutics
    • Rising Focus on Immunotherapy and CAR-T Cell Therapy Drives Innovation in Leukemia Treatment
    • Technological Innovations in Biomarker Discovery Enhance Development of Targeted Therapies
    • Expanding Use of Leukemia Therapeutics in Pediatric Oncology Generates New Opportunities
    • Rising Importance of Precision Medicine and Genomics in Leukemia Research Strengthens Demand
    • Technological Advancements in Monoclonal Antibodies and Small Molecule Inhibitors Expand Market Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Leukemia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Leukemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chronic Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chronic Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Acute Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Acute Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Acute Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • Active Players in United States
    • TABLE 35: USA Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • CANADA
    • Active Players in Canada
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • Active Players in Japan
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • CHINA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • Active Players in China
    • TABLE 62: China Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Leukemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • Active Players in France
    • TABLE 83: France Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • Active Players in Germany
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • ITALY
    • Active Players in Italy
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • Active Players in United Kingdom
    • TABLE 110: UK Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • SPAIN
    • Active Players in Spain
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • Active Players in Russia
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • Active Players in Rest of Europe
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Leukemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • Active Players in Australia
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • INDIA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • Active Players in India
    • TABLE 167: India Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • Active Players in South Korea
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • Active Players in Rest of Asia-Pacific
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Leukemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • Active Players in Argentina
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • Active Players in Brazil
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • MEXICO
    • Active Players in Mexico
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • Active Players in Rest of Latin America
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Leukemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • IRAN
    • Active Players in Iran
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • Active Players in Israel
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • Active Players in Saudi Arabia
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • Active Players in United Arab Emirates
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • Active Players in Rest of Middle East
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • Active Players in Africa
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제